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Abstract 
Purpose: Iron deficient athletes are often treated with long term, low dose iron therapy. Such 
treatments may be efficacious in correcting iron deficiency, however the effect on acute and 
chronic iron metabolism and subsequent endurance capacity is less clear. Methods: Fifteen 
national and international standard runners were identified as iron deficient non-anaemic (IDNA) 
and assigned to either an intravenous iron treatment or placebo group. Participants completed 3 
exercise tests to volitional exhaustion; before treatment, within 24 h and 4 weeks after treatment. 
Results: Serum ferritin, serum iron, transferrin saturation were significantly improved in the iron 
group following intervention and compared to placebo (p < 0.05). Hepcidin levels were 
significantly greater before and after exercise following the iron injection (p < 0.05) and this was 
independent of changes in interleukin-6. There were no differences between groups in red cell 
indices, total haemoglobin mass, V! O2max, sub-maximal blood lactate, running economy, ratings 
of perceived exertion or time to exhaustion (p > 0.05). Conclusion: A single 500 mg intravenous 
iron injection is effective for improving iron status for at least 4 weeks but this does not lead to 
an improved aerobic capacity. This investigation suggests that iron availability supersedes 
inflammation in the regulation of hepcidin in IDNA endurance athletes following acute 
intravascular iron injection treatment. 
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Introduction 
Iron deficiency is commonly identified in endurance runners due to prolonged training 
and repeated ground impacts causing iron losses through a number of potential mechanisms (1, 
37). Iron deficiency is associated with oxidative stress (16), impaired mitochondrial electron 
transport and protein synthesis (1) and can lead to compromised erythropoiesis (iron deficient 
anaemia, IDA; 35). It is well established that when iron deficiency causes IDA it leads to 
impaired oxygen carrying capacity and endurance performance (8). Although, the effect of iron 
deficiency non-anaemia (IDNA) is less clear, iron treatment in the form of either oral iron 
supplementation or parenteral iron are appealing interventions for endurance athletes with IDNA. 
Iron therapy is widely reported to be effective at replenishing body iron stores (3, 8, 9, 
11, 24, 40), and in some reports has led to improvements in V! O2max (9), sub-maximal cycling 
efficiency and time trial performance (11), fractional utilisation of peak V! O2 (40) and total 
haemoglobin mass (tHb-mass; 9) in IDNA endurance athletes. However, the restoration of iron 
stores does not guarantee an improvement in aerobic capacity or indices of endurance 
performance (3, 11, 24). Moreover, improvements in iron status following treatment are often 
transient, with observations of serum ferritin (sFer) returning to pre-treatment levels within 
weeks (23), the cause of which is currently unknown. Previous investigations into iron 
supplementation have largely described the outcome of the intervention but have not addressed 
the regulation of iron metabolism or the impact that the iron treatment may have upon it. 
The peptide hormone hepcidin is the master regulator of iron metabolism. Hepcidin 
controls iron absorption from the diet and the export of iron from hepatocytes and macrophages 
(18). Regulation of hepcidin is strongly mediated by iron availability, inflammation and hypoxia 
(20), stimuli that endurance athletes may be regularly exposed to. The link between hepcidin and 
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inflammation (7) has been established in both mice (20) and human models (17, 18). Indeed, 
exercise induced increases in the inflammatory marker interleukin-6 (IL-6) have preceded 
increases in hepcidin in active (19), trained (25) and well trained runners (26, 33). However, elite 
athletes may experience less of an inflammatory response following exercise than those who are 
less well trained due to adaptation (12), which may hypothetically alter the hepcidin response in 
this population. In addition, post-exercise hepcidin is correlated with baseline sFer but not IL-6, 
suggesting that iron availability supersedes inflammation in the regulation of hepcidin in 
individuals who are iron deficient (26). Therefore, the influence of iron availability on hepcidin 
is a key factor in the regulation of iron metabolism in iron deficient endurance athletes, yet it is 
currently not known how treating iron deficiency with intravenous iron will influence hepcidin 
and iron metabolism in elite endurance athletes. 
The aim of this study was firstly to characterise the response of hepcidin and iron 
metabolism to iron treatment in the form of a single, high dose intravascular injection. 
Furthermore, given the lack of consensus on the value of iron repletion at improving endurance 
performance in previous studies, a second aim was to test the hypothesis that the iron injection 
would enhance aerobic capacity in IDNA elite distance runners. 
 
Materials and methods 
Participants 
National and international standard endurance runners from the London Marathon 
endurance performance group at St Mary’s University, London received a full blood test for 
assessment of red cell indices and iron status. Of 45 athletes screened, 15  (9 female, age 21 ± 2 
years; height 169.1 ± 4.0 cm; body mass 59.3 ± 4.3 kg; V! O2max 64.5 ± 5.7 ml·kg-1·min-1; 6 male, 
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age 20 ± 1 years; height 178.8 ± 5.9 cm; body mass 65.2 ± 3.5 kg; V! O2max 76.7 ± 2.7 ml·kg-1·min-
1) were classified as iron deficient but not anaemic (females: sFer < 30.0 µg·L-1, Hb > 12.0 g·dL-
1; males: sFer < 40 µg·L-1, Hb > 12.0 g·dL-1). It is acknowledged that there is no universal 
consensus for the classification of IDNA in athlete populations, with a variety of cut-offs for sFer 
appearing in the literature (3, 9, 29). An upper limit of 40 µg/L is used in the present 
investigation for males as this is considered iron deficient by the national governing body for 
Track and Field to which the athletes are affiliated, and whereby medical practitioners would 
treat and monitor the iron status of each athlete.  All participants gave written informed consent 
prior to participating in the study, and met the exclusion criteria of current or recent pregnancy 
(12 months), recent illness or blood donation. The study protocol was approved by both the 
National Health Service (NHS; 12/LO/0513) and the St Mary’s University ethics committees. 
Participants were instructed not to deviate from their normal dietary practices, to refrain from 
iron supplementation throughout the study and to attend all laboratory trials in a well-hydrated 
state, at the same time of day, and to refrain from strenuous exercise during the preceding 24 
hours (h). 
 
Experimental Overview 
The study used a double-blind, randomised controlled design. Participants were assigned 
to either an iron treatment group (n = 7) or placebo group (n = 8), ensuring males and females 
were split evenly between groups and completed three discontinuous incremental treadmill tests 
to volitional exhaustion. Treadmill test one was performed prior to receiving either an 
intravenous iron injection (500 mg Ferinject, Vifor Pharma Ltd, Opfikon, Switzerland) or 
placebo injection (0.9% sterile saline solution), carried out in hospital conditions and under the 
AC
CE
PT
ED
Copyright © 2014 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.
 7 
supervision of a doctor. Treadmill test 2 was completed 7 days later and within 24 h of the 
participants receiving the treatment; and treadmill test 3 took place 4 wks post treatment. Venous 
blood samples were taken immediately before, immediately after, 3 hrs after and 24 hrs after 
each treadmill test for the assessment of sFer, serum iron (sFe), transferrin (sTf), transferrin 
saturation (Tsat), soluble transferrin receptor (sTfR) and hepcidin. Additionally, measurements 
of tHb-mass were taken after each of the treadmill tests. 
 
Treadmill Tests 
The treadmill test consisted of two parts: 1) a discontinuous incremental test of 3 minute 
stages, beginning at an initial predetermined intensity of 12-15 km·h-1 and increasing by 1 km·h-1 
at the start of each stage until blood lactate concentration exceeded 4 mMol·L-1. Participants 
completed an average of 6 stages (range 5-7). Running was interrupted for 30 s at the end of each 
stage to allow for earlobe capillary blood sampling, whereby 20 µl of blood was obtained and 
immediately dropped into haemolysing solution for subsequent analysis of blood lactate using an 
automated analyser (Biosen C-Line, EFK Diagnostic, Barleben, Germany). Heart rate was 
recorded continuously throughout the test at 5 s intervals (Polar S610, Polar electro, Kempele, 
Finland); 2) Following a 10 min active recovery period of treadmill walking at a self-selected 
speed, subjects completed a further incremental test for the determination of V! O2max, which 
consisted of 1% gradient increases each minute at a constant running speed (1-2 km.hr-1 below 
the running speed during the final stage of part one) until volitional exhaustion. Oxygen uptake 
( V! O2), expired carbon dioxide (V! CO2) and ventilation ( V! E) were sampled and measured 
continuously throughout both parts of the treadmill test using an on-line breath-by-breath 
analyser (Oxycon Pro, Jaeger, Hoechberg, Germany). The gas analyser was calibrated before 
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each test using oxygen and carbon dioxide gases of known concentrations (Cryoservice, 
Worcester, UK) and the flow sensor was calibrated using a 3-litre syringe (Viasys Healthcare 
GmbH, Hoechberg, Germany) according to manufacturers instructions. Sub-maximal V! O2 was 
determined via a final minute average for each stage. V! O2max established via a rolling 30 s 
average, after eliminating values that are outside four standard deviations of the midpoint of a 
rolling 20 breath mean (attributed to ‘noise’; 30). Rate of perceived exertion (RPE; 4) was 
assessed during the 30s interruption for blood sampling, by asking participants to point to a 
number on a scale from 6 (no exertion) to 20 (maximal exertion) in order to rate their overall 
effort over the previous 3 minute running bout. 
 
Iron Treatment 
Athletes were randomised to iron treatment or placebo injection by a researcher blinded 
to the treadmill test data. Athletes were blinded to the intervention received. The iron or placebo 
injection was given by slow intravenous injection over 10 minutes through covered syringe and 
tubing and the athlete’s arm was shielded from vision, perfomed at a hospital location (Hospital 
of St John and St Elizabeth, London). The researcher (NP) who performed the iron injection did 
not disclose which intervention the athlete had received to the physiology testers (RB and CP) 
until the end of the trial period. 
 
Haematology and Biochemistry 
Venous blood was collected via venepuncture of an anticubital vein in the forearm. A 10 
ml SST gel Vacutainer (BD, Oxford, England) was filled and allowed to clot for 30 min at room 
temperature. The sample was then centrifuged at 4 °C and 3000 rpm for 10 min. Serum was then 
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drawn off by syringe and divided into 1 ml aliquots and immediately frozen at -80 °C until 
analysis. Serum iron (sFe), sFer and transferrin (sTf) were assayed on the Architect ci6200 
platform (Abbott Diagnostics Ltd, Maidenhead, UK), with inter and intra-assay coefficients of 
variation (CV) of 5% and 6% respectively. Serum iron was measured using a colourmetric 
method, sFer was measured using a solid-phase; two-site chemiluminescent immunometric assay 
(ICMA), and sTf was measured using a turbidimetric method. Transferrin saturation (Tsat) was 
calculated using the following formula 
Iron x 100/transferrin x 12.57 x 2 
Hepcidin was measured using an in-house immunoassay with antibodies specific for human 
hepcidin-25 (5). Soluble transferrin receptor (sTfR) and IL-6 were measured using commercial 
enzyme immunosorbent immunoassays (ELISA) using two specific monoclonal antibodies 
(R&D Systems, Abingdon, UK). 
 
Blood Volume and Total Haemoglobin Mass 
Blood volume and tHb-mass were assessed and calculated using the optimised carbon 
monoxide (CO) rebreathing method described by Schmidt and Prommer (31). Briefly, a bolus of 
a known dose of CO (0.8-1.0 ml·kg-1) was rebreathed for 2 min using a specifically designed 
spirometer (Bloodtec, Bayreuth, Germany). Capillary blood samples were taken from an earlobe 
prior to and at 6 and 8 min after rebreathing began, and analysed for carboxyhaemoglobin 
(%HbCO) using spectrophotometry (OSM-80, Radiometer, Copenhagen, Denmark). CO not 
taken up by the subject was calculated using the volume of the rebreathing bag and the CO 
concentration left in it using a hand held CO gas analyser (Pac700, Drager, Lubeck, Germany). 
Seven minutes after commencing rebreathing end tidal CO concentration was measured using the 
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same CO gas analyser. tHb-mass and blood volume were then calculated using SpiCO 
measurement software (Bloodtec, Bayreuth, Germany). All measurements were taken 1 h 
following completion of the treadmill tests, with participants in a seated position 15 min prior to 
and throughout the procedure. 
 
Statistical Analysis 
Data were analysed using the Statistical Package for the Social Sciences (SPSS, Inc., Chicago, 
IL, USA). Measures of central tendency and spread are presented as mean ± SD. Sub-maximal 
V
! O2, and blood lactate ([La]) during the three treadmill tests and changes in sFer, sFe, sTf, Tsat, 
sTfR and hepcidin were analysed using a mixed analysis of variance (MANOVA) with repeated 
measures (Treatment condition x measurement time point). A one-way analysis of variance 
(ANOVA) was used to analyse the effect of the iron treatment on tHb-mass, blood volume and 
V
! O2max. When the assumption of sphericity was violated, the Greenhouse-Geisser correction was 
used. In the event of a significant outcome a post-hoc test with Bonferroni adjustments was 
applied to identify where differences lay. The level of significance was set at p < 0.05 for all 
analyses. In order to provide a more insightful interpretation of the data, the actual p value is 
given for significant outcomes. 
 
Results 
Iron Indices 
There were no significant between-group differences prior to treatment (baseline) in sFer, 
sFe, sTf, Tsat, sTfR, Il-6 or hepcidin (figures 1, 2, 3 and table 1). After treatment a significant 
main effect of iron treatment group was revealed for sFer (p=0.001). Significant effects of time 
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point (p=0.001) and time point x treatment group interaction (p=0.001) revealed that sFer 
increased within 24 h of the iron injection in the iron group and this was maintained during all 
remaining time points up to 4 weeks after treatment (figure 1). Serum ferritin did not change in 
the placebo group. 
Prior to treatment no significant main effect of treatment group (p=0.995) or treatment 
group x time point interaction (p=0.943) was observed for hepcidin. However, there was a 
significant main effect of time point (p=0.009) but Post hoc tests were unable to identify where 
the effects of time point were. Twenty-four hours after the iron injection a significant main effect 
of treatment group was observed for hepcidin (p=0.004), with the iron group having significantly 
higher hepcidin values at all time points compared to the placebo group (figure 2). There was 
also a significant effect of time point (p=0.016) but no significant time point x treatment group 
interaction (p=0.398). The Bonferroni adjustments were unable to identify where the significant 
time point effects lay. Four weeks after the treatment there were significant main effects of 
treatment group (p=0.009), time point (p=0.004) and time point x treatment group interaction 
(p=0.033), with the iron group having a significantly higher hepcidin response 3 h post-exercise. 
Interleukin-6 increased immediately after each exercise test in both the iron and placebo 
groups (p=0.001; figure 3) but there were no treatment effects (p=0.659) or significant time point 
x treatment group interactions (p=0.569). Serum iron (p=0.001) and Tsat (p=0.001) were 
significantly affected by treatment and both measures observed significant time point (p=0.001) 
effects and treatment group x time point interactions (p=0.001). Following the iron injection both 
sFe and Tsat (table 1) increased significantly within 24 h compared to the placebo group but by 4 
weeks after both had returned to pre-treatment levels. 
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 Serum transferrin was not affected by treatment (p=0.150) and there was no treatment 
group x time point interaction (p=0.174). A significant effect of time point (p=0.001) was 
observed revealing an increase in sTf in both groups immediately after the pre-treatment 
treadmill test when compared to pre-test levels (table 1). There was a significant effect of 
treatment group on sTfR (p=0.014) but no significant effect of time point (p=0.121) or a 
significant treatment group x time point interaction (p=0.163; table 1). 
 
Red Cell Indices & Treadmill Data 
Red cell indices and treadmill data are presented in tables 2 and 3 respectively. There 
were no significant differences between groups in red cell indices, V! O2max, vV! O2max, economy, 
speed at 2 mmol·L [La], speed at 4 mmol·L [La], time to exhaustion, RPE or tHb-mass at 
baseline or following iron treatment (p>0.05). 
 
Discussion 
Iron treatments are clearly effective at improving the iron status of IDNA endurance 
athletes in the short-term, however the improvements in sFer levels are often transient and return 
to iron deficient levels within weeks (23). Previous investigations into iron supplementation have 
largely described the outcome of the intervention but have not addressed the regulation of iron 
metabolism or the impact that the iron treatment may have upon it. The peptide hepcidin is 
proposed to be the major regulator of iron absorption (18) and is influenced by inflammation, 
iron and hypoxia (20); these are stimuli with clear relevance to endurance athletes. Following an 
inflammatory response, possibly caused by exercise, hepcidin increases, blocking iron absorption 
and iron release from macrophages (18). Conversely, during periods of iron deficiency or 
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hypoxia, hepcidin is down regulated to allow for increased iron release and absorption. In the 
present investigation, prior to treatment, there was a significant effect of time and although the 
statistical analysis was unable to confirm which pre-treatment time point this related to, the 
effect is likely to have occurred 3 h after exercise, which is in line with reports from previous 
investigations in iron replete recreationally active (19) and trained athlete populations (26, 33); a 
likely result of an exercise induced inflammatory response and significant increases in IL-6 (19, 
25). 
The major finding, however, was the observation that when IDNA athletes are treated 
with intravenous iron the significant increase in sFer results in a post-exercise increase in 
hepcidin that is independent of changes in IL-6 (figure 2 & 3). A recent study suggested the post-
exercise hepcidin response is mediated by resting sFer levels, with low iron stores overriding 
inflammation resulting in attenuated hepcidin (26). Our data support the assertion that the level 
of iron stores supersedes inflammation in the regulation of hepcidin, with greater responses 
evident as the sFer levels were increased. However, the absence of a hepcidin response following 
exercise in individuals with sFer values commonly associated with IDNA (i.e. sFer <30 µg/L), 
was not seen here. Significant increases in hepcidin occurred after exercise at 24 h and 4 weeks 
after intravenous iron treatment (figure 2), yet there were no significant differences in IL-6 
between groups at any time point pre- or post-treatment (figure 3). This coincided with 
significant elevations in sFer (figure 1), sFe and Tsat (table 1) within 24 h of treatment and the 
maintenance of an elevated sFer at 4 wks post-treatment. The up-regulation of hepcidin, 
independent of inflammation has been shown in other settings (22, 26, 27) but this is the first 
study to show this interaction and the role hepcidin plays in iron metabolism in response to 
intravenous iron treatment in elite IDNA endurance athletes. Furthermore, the changes in 
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hepcidin regulation and iron metabolism following intravenous iron treatment had no effect on 
red cell indices or surrogate measures of endurance capacity, rejecting the hypothesis that an iron 
injection would improve the aerobic capacity of IDNA endurance athletes. 
The mechanism by which iron mediates hepcidin is currently not clear but hepcidin 
expression has shown good correlation with increased sFe and Tsat in iron-loaded mice (15). 
Talbot et al. (36) reported a suppression of hepcidin in iron replete individuals during a sojourn 
to altitude, which was overcome by prior iron loading. The decrease in hepcidin occurred until 
Tsat, but not sFer, had normalised. Indeed, in the current investigation Tsat and sFe were 
significantly elevated 24 h post iron treatment. However, this does not explain the hepcidin 
response to exercise 4 wk after iron treatment because sFe and Tsat had returned to pre-treatment 
levels. The up-regulation of hepcidin has previously been reported to occur in times of iron 
overload in healthy, non-endurance trained, volunteers following oral iron supplementation of 65 
mg per day for 3 days (18). The increased hepcidin response in the IG following exercise at 24 h 
and 4 wks post-iron treatment in the present study coincided with significantly increased sFer. 
Ferritin has been shown to regulate the signalling molecule bone morphogenetic protein 6 
(BMP6) in mice, thereby serving as an iron store regulator, mediating hepcidin expression in 
response to iron overload (6). It is plausible that despite the athletes having initial sFer levels 
well below the clinical criteria for IDNA (24), this actually represents a state of normal iron 
metabolism for this population. The substantial increase in iron after the injection may therefore 
have caused an unnecessary increase in iron availability, reminiscent of iron overload, and the 
stimulation of hepcidin in order to prevent further iron absorption. Moreover, sFer is reported to 
correlate with markers of hydroxyl radical formation, an indicator of oxidative damage (38). It is 
argued that sFer originates from cell damage (13) and does not contain its full compliment of 
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iron (21), which suggests that the lost iron initiates oxidative stress. It is possible that the IL-6 
independent increases in hepcidin following exercise observed in the present study are also in 
response to oxidative stress, although we do not have any data to support this contention. 
Soluble transferrin receptor is considered to be an accurate marker of iron deficiency (2) 
and benefits from being unaffected by exercise-induced inflammation (35). Previously, oral iron 
supplementation in IDNA subjects has resulted in a significant decrease in sTfR accompanied by 
increases in sFer (40). Conversely, sTfR was reportedly unchanged in female IDNA endurance 
athletes following an iron injection (24). The present investigation also found no significant 
changes in sTfR in either the iron or placebo group following treatment, despite increases in sFer 
in the iron group. The lack of change in sTfR in response to the iron injection might suggest that 
sTfR levels in IDNA individuals are within the normal range and despite low sFer, iron 
requirements and availability are not yet compromised. Furthermore, the lack of an impact upon 
V
! O2max, vV! O2max, running economy, [La] at sub-maximal running speeds, TTE, RPE, tHb-mass 
(table 3) or red cell indices (table 2) following the iron injection provides additional evidence 
that low sFer levels prior to iron treatment do not lead to any negative outcomes, notwithstanding 
the limitations of the present study. Moreover, the current evidence raises the possibility that 
clinical ranges for sFer are redundant in endurance athletes, particularly when used as a single 
marker of iron storage. The lack of any improvement in aerobic capacity and surrogate measures 
of endurance performance in the present study is in contrast to a recent investigation which 
reported likely improvements in tHb-mass and V! O2max following iron injection but not oral 
supplementation (9). However, the increases in tHb-mass observed by Garvican et al. (9) 
following iron injection (2.7% after 6 weeks & 1.9% after 8 weeks) fall close to and within the 
typical measurement error associated with CO rebreathing (2.2%; 10). Additionally, the average 
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oscillation for tHb-mass in athletes over a year is 4.6% (28), which suggests it may be difficult to 
associate very small changes in tHb-mass to intravenous iron treatment. 
The present study provides further evidence that the up-regulation of the post-exercise 
hepcidin response following iron treatment represents a major consideration when prescribing 
iron treatments for IDNA athletes. It is accepted that the up-regulation of hepcidin inhibits iron 
absorption from the diet and iron release to the circulation (14, 18) and the rise in hepcidin 
observed following an acute exercise bout appears to be greater following IV iron treatment, as 
demonstrated in the current investigation. This effect may inadvertently result in a reduction in 
iron absorption, which if continued over a prolonged period, may be contrary to the intended 
goal of enhancing the iron status of the athlete. Further in depth pharmacokinetic studies may be 
necessary to evaluate the mechanistic relationship between hepcidin, sFer and IV iron 
absorption. One consideration is the dose protocol utilised. It is possible that the single dose of 
500 mg used in the current investigation was too high and the increased hepcidin response was 
the consequence, whereas a smaller dose may not have elicited a response of such magnitude, 
potentially causing less disruption to iron homeostasis. It would be beneficial for future research 
to focus on the long-term hepcidin response to iron treatment and the dose – response 
relationship in markers of iron status. In addition, a previous investigation has proposed an sFer 
cut-off value of <30 µg/L to classify IDNA based on the lack of a post-exercise response in this 
population (26). Although these are useful data to begin to determine a precise classification, 
which is currently elusive, confounding factors in the study are apparent, such as a variety of 
exercise intensities and durations used; a small number of non-elite athletes and the individual 
variation in the sFer/hepcidin interaction. Indeed, substantial hepcidin responses were observed 
in the present investigation in some individuals despite sFer values <30 µg/L. Therefore, caution 
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is warranted and the individual variability in the hepcidin response needs to be considered, 
particularly if using a sFer cut-off of  <30 µg/L as a basis for the diagnosis and treatment of 
IDNA in elite athletes. 
The present investigation is limited by a lack of dietary control. The athletes were 
instructed to continue with their regular dietary practice and therefore there was no control of 
iron intake from food sources. However, in practice it is unlikely that athletes at this level of 
performance would deviate dramatically from their normal diet at any one time and vast changes 
would be required to significantly alter total iron intake during the time course of this study. 
Another limitation is the potential impact that menstrual cycle phase can have on indices of iron 
metabolism (34) and again, this was not controlled. However, although iron indices may be 
lower during menses, V! O2max, tHb-mass and the other measures of endurance capacity are 
unlikely to be affected by menstrual cycle phase (39). The training that the athletes undertook on 
a daily basis was also not under the control of this investigation, other than the standard pre-test 
requirement to reduce training intensity in the 24 hours prior to treadmill testing, which could 
have potentially influenced aerobic capacity. However, tHb-mass remains relatively stable in 
athletes of a highly trained status (32) and the measures of iron metabolism are also unlikely to 
be affected. 
 
Conclusion 
Iron treatment in the form of a single 500 mg dose of parenteral ferric carboxymaltose 
significantly raised sFer within 24 h and this was maintained for 4 weeks after treatment. 
However, the hypothesis that improved iron status would result in the enhancement of aerobic 
capacity and indices of endurance capacity is rejected, as there were no significant effects on 
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V
! O2max, sub-maximal [La], running economy, RPE or TTE. Additionally, this investigation 
revealed for the first time that iron availability supersedes inflammation in the regulation of 
hepcidin in IDNA endurance athletes following acute intravascular iron injection treatment. 
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Figure Legends 
Figure 1. Serum ferritin values for the Iron group (A) and Placebo group (B) measured 
pre-treadmill test, immediately post-treadmill test and three hours post-treadmill test. 
Measurements were replicated pre-treatment, 24 hours post-treatment and 4 weeks post-
treatment. * Significant difference (p < 0.05) between iron and placebo groups; † significant 
difference (p < 0.05) between baseline and post-treatment time points. 
 
Figure 2. Hepcidin values for the Iron group (A) and Placebo group (B) measured pre-
treadmill test, immediately post-treadmill test and three hours post-treadmill test. 
Measurements were replicated pre-treatment, 24 hours post-treatment and 4 weeks post-
treatment. * Significant difference (p < 0.05) between iron and placebo groups; † significant 
difference (p < 0.05) between pre-exercise and post-exercise time points. 
 
Figure 3. Interleukin-6 values for the Iron group (A) and Placebo group (B) measured pre-
treadmill test, immediately post-treadmill test and three hours post-treadmill test. 
Measurements were replicated pre-treatment, 24 hours post-treatment and 4 weeks post-
treatment. * Significant difference (p < 0.05) between iron and placebo groups; † significant 
difference (p < 0.05) between baseline and post-treatment time points. 
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Table Legends 
Table 1. Iron metabolism data measured pre-exercise, immediately after exercise and 3 hours 
after exercise pre-treatment, 24 hours post-treatment and 4 weeks post-treatment. 
 
Table 2. Red cell indices measured pre-treatment and 4 weeks post-treatment. 
 
Table 3. Total Haemoglobin mass and exercise test data taken pre-treatment, 24 hours post-
treatment and 4 weeks post-treatment 
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Table 1. Iron metabolism data measured pre-exercise, immediately after exercise and 3 hours after exercise pre-treatment,  
24 hours post-treatment and 4 weeks post-treatment. 
 !!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Significant difference (p < 0.05) between iron and placebo groups; † significant difference (p < 0.05) between pre-treadmill test, pre-treatment time point.!!
  Pre-Treatment 24 Hours Post-Treatment 4 Weeks Post-Treatment 
 Measure Group Pre  24 h Post 4 wks Post Pre  24 h Post 4 wks Post Pre  24 h Post 4 wks Post 
Serum Iron, umol·L IG 20.3 23.2 20.6 70.7*† 72.8*† 64.0*† 23.4 25.7 21.2 
  (7.2) (8.2) (9.5) (10.0) (8.5) (11.9) (4.0) (3.3) (4.9) 
 PG 19.3 22.5 21.8 20.6 23.4 21.3 15.1 17.9 17.3 
  (6.9) (7.3) (8.0) (14.3) (15.5) (11.9) (6.2) (9.0) (6.9) 
Tsat, % IG 33.1 34.3 32.4 113.2*† 110.6*† 104.7*† 43.2 45.1 39.2 
  (12.0) (13.9) (15.0) (8.4) (6.9) (5.9) (6.3) (6.0) (8.4) 
 PG 29.1 31.2 31.4 30.3 31.5 30.9 20.9 24.8 24.8 
  (11.3) (11.8) (12.6) (19.7) (19.6) (17.4) (11.2) (12.0) (10.5) 
sTf, g·L IG 2.5 2.7 2.6 2.5 2.6 2.4 2.2 2.3 2.2 
  (0.3 (0.2) (0.2) (0.3) (0.3) (0.4) (0.4) (0.3) (0.3) 
 PG 2.7 2.9 2.8 2.8 3.0 2.8 2.7 2.9 2.8 
  (0.4) (0.4) (0.6) (0.5) (0.4) (0.4) (0.4) (0.4) (0.4) 
sTfR, nm·L IG 19.4 21.2 19.6 20.4 21.3 20.3 19.4 19.9 19.0 
  (2.9) (2.1) (2.8) (3.1) (2.2) (3.1) (2.6) (2.4) (2.4) 
 PG 23.2 23.4 21.8 21.4 23.1 21.3 22.1 23.4 22.1 
  (3.0) (2.1) (2.5) (2.7) (3.1) (3.1) (2.1) (2.8) (2.0) 
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Table 2. Red cell indices measured pre-treatment and 4 weeks post-treatment.!
 Placebo Group Iron group 
  Pre 4 wks Post Pre 4 wks Post 
Haemoglobin, g·L-1 143.6 138.7 140.2 137.2 
  (9.0) (11.7) (15.4) (13.8) 
Haematocrit, L·L 0.426 0.406 0.415 0.414 
  (0.021) (0.024) (0.032) (0.025) 
Mean Cell Volume, fL-1 89.13 88.29 90.27 92.98 
  (3.72) (2.75) (4.46) (5.95) 
Mean Cell Hb, pg 30.01 30.06 30.38 30.70 
  (1.37) (1.28) (1.59) (1.51) 
Mean Cell Hb Conc, g·L-1 337.25 341.29 337.17 330.83 
  (8.38) (11.59) (13.93) (15.14) 
RDW, % 13.08 13.04 12.70 12.92 
  (0.78) (0.68) (0.68) (0.58) 
Red Cell Count, 10*12·L-1 4.7938 4.6171 4.6083 4.4750 
  (0.3046) (0.3541) (0.4271) (0.4428) 
Red Cell Folate, µg·L-1 269.63 245.19 265.70 238.42 
  (133.51) (118.18) (110.41) (67.22) 
B12, ng·L-1 482.75 476.29 567.00 573.00 
  (117.66) (172.44) (175.03) (175.87) 
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Table 3. Total Haemoglobin mass and exercise test data taken pre-treatment, 24 hours  
post-treatment and 4 weeks post-treatment. !!!!!!!!!!!!!!!!!!!!!
 Placebo Group Iron Group 
  Pre 
Treatment 
24 h Post 
Treatment 
4 wks Post 
Treatment 
Pre 
Treatment 
24 h Post 
Treatment 
4 wks Post 
Treatment 
tHb, g·kg-1 12.15 12.16 12.43 14.13 13.88 13.12 
  (1.53) (1.84) (2.10) (1.93) (1.77) (1.72) 
VO2max, ml·kg-1·min-1 64.40 64.83 64.27 73.02 71.60 70.30 
  (10.22) (9.56) (7.35) (4.80) (6.78) (5.29) 
Economy, ml·kg-1·km-1 220.13 216.63 215.29 221.33 217.00 218.00 
  (3.14) (10.02) (10.11) (6.12) (9.83) (22.27) 
vVO2max, km·h-1 17.51 17.93 17.90 19.83 20.33 19.80 
  (2.60) (2.50) (1.95) (1.53) (1.55) (1.61) 
Speed @ 2mmol·L, km·h-1 14.42 14.55 15.10 16.43 16.67 16.54 
  (2.58) (2.55) (1.96) (1.63) (1.24) (1.52) 
Speed @ 4mmol·L, km·h-1 16.20 16.15 16.82 18.23 18.24 18.01 
  (2.43) (2.47) (1.91) (1.80) (1.26) (1.50) 
TTE, s 370.25 365.50 352.86 350.86 369.43 373.33 
  (29.79) (35.66) (64.14) (26.46) (42.16) (48.10) 
RPE, Borg 6-20 12.88 12.68 12.29 13.89 12.96 12.95 
  (0.95) (1.12) (1.47) (2.25) (1.86) (1.99) 
AC
CE
PT
ED
Copyright © 2014 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.
